Endocannabinoids and striatal function: Implications for addiction-related behaviours

Behavioural Pharmacology

Volumn 26, Issue , 2015, Pages 59-72

  Moreira, Fabricio A ^a,b   Jupp, Bianca ^b   Belin, David ^b   Dalley, Jeffrey W ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

anxiety; compulsivity; dopamine; impulsivity; nucleus accumbens; prefrontal cortex

Indexed keywords

ACYLGLYCEROL LIPASE; CANNABINOID; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; CANNABINOID RECEPTOR AGONIST;

ANXIETY; ARTICLE; BRAIN FUNCTION; DRUG DEPENDENCE; DRUG METABOLISM; DRUG SELECTIVITY; HUMAN; IMPULSIVENESS; NONHUMAN; STRESS; STRIATE CORTEX; ANIMAL; BEHAVIOR, ADDICTIVE; CORPUS STRIATUM; DRUG DESIGN; DRUG EFFECTS; ETIOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REWARD; SUBSTANCE-RELATED DISORDERS;

ANIMALS; ANXIETY; BEHAVIOR, ADDICTIVE; CANNABINOID RECEPTOR AGONISTS; CORPUS STRIATUM; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; IMPULSIVE BEHAVIOR; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 84922106201     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000109     Document Type: Article

References (216)

1. Adams JB, Heath AJ, Young SE, Hewitt JK, Corley RP, Stallings MC (2003). Relationships between personality and preferred substance and motivations for use among adolescent substance abusers. Am J Drug Alcohol Abuse 29:691-712.
2. Adriani W, Caprioli A, Granstrem O, Carli M, Laviola G (2003). The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 27:639-651.
3. Ansquer S, Belin-Rauscent A, Dugast E, Duran T, Benatru I, Mar AC, et al. (2014). Atomoxetine decreases vulnerability to develop compulsivity in high impulsive rats. Biol Psychiatry 75:825-832.
4. Arguello PA, Jentsch JD (2004). Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berl) 177:141-150.
5. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106.
6. Bambico FR, Cassano T, Dominguez-Lopez S, Katz N, Walker CD, Piomelli D, et al. (2010). Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 35:2083-2100.
7. Bari A, Robbins TW (2013). Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol 108:44-79.
8. Batista LA, Gobira PH, Viana TG, Aguiar DC, Moreira FA (2014). Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behav Pharmacol 25:425-433.
9. Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ (2008). High impulsivity predicts the switch to compulsive cocaine-taking. Science 320:1352-1355.
10. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ (2009). Parallel andinteractive learning processes within the basal ganglia: relevance for theunderstanding of addiction. Behav Brain Res 199:89-102.
11. Belin D, Belin-Rauscent A, Murray JE, Everitt BJ (2013). Addiction: failure of control over maladaptive incentive habits. Curr Opin Neurobiol 23:564-572.
12. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097.
13. Bergamaschi MM, Queiroz RH, Chagas MH, Linares IM, Arrais KC, de Oliveira DC, et al. (2014). Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol 29:94-99.
14. Blanchard DC, Summers CH, Blanchard RJ (2013). The role of behavior in translational models for psychopathology: functionality and dysfunctional behaviors. Neurosci Biobehav Rev 37:1567-1577.
15. Boomhower SR, Rasmussen EB, Doherty TS (2013). Impulsive-choice patterns for food in genetically lean and obese Zucker rats. Behav Brain Res 241:214-221.
16. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479-486.
17. Canteras NS, Resstel LB, Bertoglio LJ, Carobrez Ade P, Guimaraes FS (2010). Neuroanatomy of anxiety. Curr Top Behav Neurosci 2:77-96.
18. Cappell H, Herman CP (1972). Alcohol and tension reduction. A review. Q J Stud Alcohol 33:33-64.
19. Caprioli D, Sawiak SJ, Merlo E, Theobald DE, Spoelder M, Jupp B, et al. (2014). Gamma aminobutyric acidergic and neuronal structural markers in the nucleus accumbens core underlie trait-like impulsive behavior. Biol Psychiatry. 75:115-123.
20. Cardinal RN, Winstanley CA, Robbins TW, Everitt BJ (2004). Limbic corticostriatal systems and delayed reinforcement. Ann N Y Acad Sci 1021:33-50.
21. Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R (2006). Characterizingcognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 10:117-123.
22. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012). Endocannabinoid signaling and synaptic function. Neuron 76:70-81.
23. Chen J, Paredes W, Lowinson JH, Gardner EL (1990). Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190:259-262.
24. Chiu CQ, Puente N, Grandes P, Castillo PE (2010). Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 30:7236-7248.
25. Cleck JN, Blendy JA (2008). Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest 118:454-461.
26. Coccaro EF, Sripada CS, Yanowitch RN, Phan KL (2011). Corticolimbic function in impulsive aggressive behavior. Biol Psychiatry 69:1153-1159.
27. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002). SR141716, a central cannabinoid (CB(1) receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
28. Cousijn J, Snoek RW, Wiers RW (2013). Cannabis intoxication inhibits avoidance action tendencies: a field study in the Amsterdam coffee shops. Psychopharmacology (Berl) 229:167-176.
29. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87.
30. Cryan JF, Sweeney FF (2011). The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol 164:1129-1161.
31. Dalley JW, Roiser JP (2012). Dopamine, serotonin and impulsivity. Neuroscience 215:42-58.
32. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Lääne K, et al. (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267-1270.
33. Dalley JW, Everitt BJ, Robbins TW (2011). Impulsivity, compulsivity, and top-down cognitive control. Neuron 69:680-694.
34. De Bruin NM, Lange JH, Kruse CG, Herremans AH, Schoffelmeer AN, van Drimmelen M, et al. (2011). SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res 217:408-415.
35. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154.
36. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN (2003). Cannabinoidmodulation of the reinforcing and motivational properties of heroin andheroin-associated cues in rats. Psychopharmacology (Berl) 168:164-169.
37. de Wit H (2009). Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 14:22-31.
38. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
39. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
40. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increasesynaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
41. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455.
42. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691.
43. Dickman SJ (1990). Functional and dysfunctional impulsivity: personality and cognitive correlates. J Pers Soc Psychol 58:95-102.
44. Diergaarde L, Pattij T, Poortvliet I, Hogenboom F, de Vries W, Schoffelmeer AN, De Vries TJ (2008). Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biol Psychiatry 63:301-308.
45. Dilleen R, Pelloux Y, Mar AC, Molander A, Robbins TW, Everitt BJ, et al. (2012). High anxiety is a predisposing endophenotype for loss of control over cocaine, but not heroin, self-administration in rats. Psychopharmacology (Berl) 222:89-97.
46. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
47. Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, et al. (2013). Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl) 226:307-319.
48. Eagle DM, Bari A, Robbins TW (2008). The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) 199:439-456.
49. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, et al. (2006). Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183:394-403.
50. Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ (2009). High impulsivity predicts relapse to cocaine-seeking after punishment-induced abstinence. Biol Psychiatry 65:851-856.
51. Economidou D, Theobald DE, Robbins TW, Everitt BJ, Dalley JW (2012). Norepinephrineand dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleusaccumbens. Neuropsychopharmacology 37:2057-2066.
52. Egertova M, Giang DK, Cravatt BF, Elphick MR (1998). A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 265:2081-2085.
53. El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET (2012). Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuropsychopharmacol Biol Psychiatry 38:36-50.
54. Ersche KD, Turton AJ, Pradhan S, Bullmore ET, Robbins TW (2010). Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry 68:770-773.
55. Ersche KD, Turton AJ, Chamberlain SR, Müller U, Bullmore ET, Robbins TW (2012). Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry 169:926-936.
56. Evenden J (1999a). Impulsivity: a discussion of clinical and experimental findings. J Psychopharmacol 13:180-192.
57. Evenden JL (1999b). Varieties of impulsivity. Psychopharmacology (Berl) 146:348-361.
58. Everitt BJ (2014). Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories-indications for novel treatments of addiction. Eur J Neurosci 40:2163-2182.
59. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
60. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW (2008). Neural mechanisms underlying the vulnerability to develop compulsive drugseeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 363:3125-3135.
61. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, et al. (2007). An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 53:1-16.
62. Feldman HM, Reiff MI (2014). Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 370:838-846.
63. Fillmore MT, Rush CR (2002). Impaired inhibitory control of behavior in chronic cocaine users. Drug Alcohol Depend 66:265-273.
64. Fitzgerald ML, Shobin E, Pickel VM (2012). Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry 38:21-29.
65. French ED (1997). Delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226:159-162.
66. Garavan H, Hester R (2007). The role of cognitive control in cocaine dependence. Neuropsychol Rev 17:337-345.
67. Garcia-Gutierrez MS, Garcia-Bueno B, Zoppi S, Leza JC, Manzanares J (2012). Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol 165:951-964.
68. Gerdeman GL, Schechter JB, French ED (2008). Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology 33:2747-2759.
69. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
70. Gonzalez R, Schuster RM, Mermelstein RJ, Vassileva J, Martin EM, Diviak KR (2012). Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol 34:962-976.
71. Griebel G, Holmes A (2013). 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12:667-687.
72. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013). Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34:637-644.
73. Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352:1611-1616.
74. Haring M, Marsicano G, Lutz B, Monory K (2007). Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146:1212-1219.
75. Harrison AA, Everitt BJ, Robbins TW (1999). Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination. Behav Brain Res 100:99-112.
76. Hayton SJ, Mahoney MK, Olmstead MC (2012). Behavioral traits predicting alcohol drinking in outbred rats: an investigation of anxiety, novelty seeking, and cognitive flexibility. Alcohol Clin Exp Res 36:594-603.
77. Hawton K, van Heeringen K (2009). Suicide. Lancet 373:1372-1381.
78. Herkenham M (1992). Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 654:19-32.
79. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
80. Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991a). Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274.
81. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991b). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
82. Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451-460.
83. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, et al. (2013). Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci 16:1291-1298.
84. Hernandez G, Oleson EB, Gentry RN, Abbas Z, Bernstein DL, Arvanitogiannis A, et al. (2014). Endocannabinoids promote cocaine-induced impulsivity and its rapid dopaminergic correlates. Biol Psychiatry 75:487-498.
85. Hester R, Garavan H (2004). Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci 24:11017-11022.
86. Hester R, Nestor L, Garavan H (2009). Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 34:2450-2458.
87. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30:484-493.
88. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M (2005). CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30:339-349.
89. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
90. Iversen L (2003). Cannabis and the brain. Brain 126:1252-1270.
91. Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 146:373-390.
92. Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, et al. (2003). Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309-318.
93. Jupp B, Dalley JW (2014). Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models. Br J Pharmacol 171:4729-4766.
94. Jupp B, Caprioli D, Dalley JW (2013). Highly impulsive rats: modelling an endophenotype to determine the neurobiological, genetic and environmental mechanisms of addiction. Dis Model Mech 6:302-311.
95. Kalivas PW, Volkow ND (2005). The neural basis of addiction: a pathology ofmotivation and choice. Am J Psychiatry 162:1403-1413.
96. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
97. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
98. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, et al. (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26:5628-5637.
99. Kessler RC, Ruscio AM, Shear K, Wittchen HU (2010). Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2:21-35.
100. Khantzian EJ (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142:1259-1264.
101. Kirby KN, Petry NM (2004). Heroin and cocaine abusers have higher discount rates for delayed rewards than alcoholics or non-drug-using controls. Addiction 99:461-471.
102. Koob GF (2008). A role for brain stress systems in addiction. Neuron 59:11-34.
103. Koob GF (2013). Negative reinforcement in drug addiction: the darkness within. Curr Opin Neurobiol 23:559-563.
104. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58.
105. Koob GF, Le Moal M (2008). Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 363:3113-3123.
106. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
107. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8:1450-1457.
108. Kreitzer AC, Regehr WG (2001). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727.
109. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ (2007). Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2:e709.
110. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ (2005). Acute marijuana effects on human risk taking. Neuropsychopharmacology 30:800-809.
111. Le Foll B, Goldberg SR (2004). Rimonabant, a CB1 antagonist, blocks nicotine conditioned place preferences. Neuroreport 15:2139-2143.
112. Lovinger DM, Mathur BN (2012). Endocannabinoids in striatal plasticity. Parkinsonism Relat Disord 18 (Suppl 1):S132-S134.
113. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. (2004). Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 15:21-27.
114. Marco EM, Adriani W, Canese R, Podo F, Viveros MP, Laviola G (2007). Enhancement of endocannabinoid signalling during adolescence: modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats. Pharmacol Biochem Behav 86:334-345.
115. Marco EM, Garcia-Gutierrez MS, Bermudez-Silva FJ, Moreira FA, Guimaraes F, Manzanares J, et al. (2011). Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 5:63.
116. Marsicano G, Lutz B (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225.
117. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534.
118. Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M, et al. (2008). Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33:1667-1679.
119. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
120. McDonald J, Schleifer L, Richards JB, de Wit H (2003). Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28:1356-1365.
121. McLaughlin PJ (2012). Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity. Behav Pharmacol 23:537-550.
122. Mechoulam R (1970). Marihuana chemistry. Science 168:1159-1166.
123. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
124. Melis M, Gessa GL, Diana M (2000). Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24:993-1006.
125. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, et al. (2004a). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707-10715.
126. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004b). Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62.
127. Merritt LL, Martin BR,Walters C, Lichtman AH, Damaj MI (2008). Theendogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 326:483-492.
128. Metrik J, Kahler CW, Reynolds B, McGeary JE, Monti PM, Haney M, et al. (2012). Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl) 223:489-499.
129. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA (2013). Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294-1301.
130. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, et al. (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593-606.
131. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC (2001). Psychiatric aspects of impulsivity. Am J Psychiatry 158:1783-1793.
132. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schutz G, et al. (2007). Genetic dissection of behavioural and autonomic effects of delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5:e269.
133. Monterosso J, Ainslie G (1999). Beyond discounting: possible experimental models of impulse control. Psychopharmacology (Berl) 146:339-347.
134. Monterosso JR, Aron AR, Cordova X, Xu J, London ED (2005). Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 79:273-277.
135. Monterosso JR, Ainslie G, Xu J, Cordova X, Domier CP, London ED (2007). Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task. Hum Brain Mapp 28:383-393.
136. Moreira FA, Crippa JA (2009). The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 31:145-153.
137. Moreira FA, Lutz B (2008). The endocannabinoid system: emotion, learning and addiction. Addict Biol 13:196-212.
138. Moreira FA, Wotjak CT (2010). Cannabinoids and anxiety. Curr Top Behav Neurosci 2:429-450.
139. Moreira FA, Kaiser N, Monory K, Lutz B (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoiddegrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54:141-150.
140. Moreira FA, Aguiar DC, Resstel LB, Lisboa SF, Campos AC, Gomes FV, et al. (2012a). Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol 26:40-55.
141. Moreira FA, Aguiar DC, Terzian AL, Guimaraes FS, Wotjak CT (2012b). Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 204:186-192.
142. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
143. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8:885-895.
144. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61-70.
145. Navarrete F, Perez-Ortiz JM, Manzanares J (2012). Cannabinoid CB(2) receptormediated regulation of impulsive-like behaviour in DBA/2 mice. Br J Pharmacol 165:260-273.
146. Navarrete F, Rodríguez-Arias M, Martín-García E, Navarro D, García-Gutiérrez MS, Aguilar MA, et al. (2013). Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology 38:2515-2524.
147. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. (2001). Functional interaction between opioid and cannabinoid receptors in drug selfadministration. J Neurosci 21:5344-5350.
148. Nestler EJ (2005). Is there a common molecular pathway for addiction? Nat Neurosci 8:1445-1449.
149. Nigg JT, Wong MM, Martel MM, Jester JM, Puttler LI, Glass JM, et al. (2006). Poor response inhibition as a predictor of problem drinking and illicit drug use in adolescents at risk for alcoholism and other substance use disorders. J Am Acad Child Adolesc Psychiatry 45:468-475.
150. Noël X, Van der Linden M, d'Acremont M, Bechara A, Dan B, Hanak C, Verbanck P (2007). Alcohol cues increase cognitive impulsivity in individuals with alcoholism. Psychopharmacology (Berl) 192:291-298.
151. Ohno-Shosaku T, Maejima T, Kano M (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729-738.
152. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514-536.
153. Ortega-Álvaro A, Ternianov A, Aracil-Fernández A, Navarrete F, García-Gutiérrez MS, Manzanares J (2013). Role of cannabinoid CB(2) receptor in the reinforcing actions of ethanol. Addict Biol[Epub ahead of print].
154. Panlilio LV, Mazzola C, Medalie J, Hahn B, Justinova Z, Drago F, et al. (2009). Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats. Psychopharmacology (Berl) 203:529-538.
155. Panlilio LV, Justinova Z, Goldberg SR (2013). Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther 138:84-102.
156. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311.
157. Pattij T, Vanderschuren LJ (2008). The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci 29:192-199.
158. Pattij T, Janssen MC, Schepers I, Gonzalez-Cuevas G, de Vries TJ, Schoffelmeer AN (2007). Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. Psychopharmacology (Berl) 193:85-96.
159. Perry JL, Carroll ME (2008). The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) 200:1-26.
160. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62:588-631.
161. Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA (1998). Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51:391-402.
162. Piazza PV, Le Moal M (1998). The role of stress in drug self-administration. Trends Pharmacol Sci 19:67-74.
163. Pickel VM, Chan J, Kearn CS, Mackie K (2006). Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 495:299-313.
164. Pierce RC, O'Brien CP, Kenny PJ, Vanderschuren LJ (2012). Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med 2:a012880.
165. Pillolla G, Melis M, Perra S, Muntoni AL, Gessa GL, Pistis M (2007). Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psychopharmacology (Berl) 191:843-853.
166. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
167. Pohorecky LA (1981). The interaction of alcohol and stress. A review. Neurosci Biobehav Rev 5:209-229.
168. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006a). High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31:2296-2303.
169. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006b). Cognition and motor control as a function of delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 85:114-122.
170. Rey AA, Purrio M, Viveros MP, Lutz B (2012). Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37:2624-2634.
171. Riegel AC, Lupica CR (2004). Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24:11070-11078.
172. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99:8384-8388.
173. Robbins TW (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163:362-380.
174. Rodriguez JJ, Mackie K, Pickel VM (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21:823-833.
175. Russo EB (2007). History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 4:1614-1648.
176. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ (2006). Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781.
177. Serrano A, Parsons LH (2011). Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241.
178. Sher KJ, Bartholow BD, Wood MD (2000). Personality and substance use disorders: a prospective study. J Consult Clin Psychol 68:818-829.
179. Shoaib M (2008). The cannabinoid antagonist AM251 attenuates nicotine selfadministration and nicotine-seeking behaviour in rats. Neuropharmacology 54:438-444.
180. Sidhpura N, Parsons LH (2011). Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology 61:1070-1087.
181. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M, et al. (2010). Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112-122.
182. Skegg K (2005). Self-harm. Lancet 366:1471-1483.
183. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
184. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. (2012). Reflection impulsivity in adolescent cannabis users: a comparison with alcoholusing and non-substance-using adolescents. Psychopharmacology (Berl) 219:575-586.
185. Spanagel R, Montkowski A, Allingham K, Stöhr T, Shoaib M, Holsboer F, Landgraf R (1995). Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology (Berl) 122:369-373.
186. Sperlagh B, Windisch K, Ando RD, Sylvester Vizi E (2009). Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int 54:452-457.
187. Starowicz K, Nigam S, Di Marzo V (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13-33.
188. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000). Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89-97.
189. Szabo B, Siemes S, Wallmichrath I (2002). Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 15:2057-2061.
190. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-2050.
191. Terzian AL, Drago F, Wotjak CT, Micale V (2011). The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors. Front Behav Neurosci 5:49.
192. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005). Ethanol selfadministration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 164:206-213.
193. Trezza V, Vanderschuren LJ (2008). Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl) 197:217-227.
194. Trezza V, Baarendse PJ, Vanderschuren LJ (2014). On the interaction between drugs of abuse and adolescent social behavior. Psychopharmacology (Berl) 231:1715-1729.
195. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
196. Van den Heuvel OA, van der Werf YD, Verhoef KM, de Wit S, Berendse HW, Wolters ECh, et al. (2009). Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci 289:55-59.
197. Van Wel JH, Kuypers KP, Theunissen EL, Toennes SW, Spronk DB, Verkes RJ, et al. (2013). Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users. Br J Pharmacol 170:1410-1420.
198. Verdejo-García A, Lawrence AJ, Clark L (2008). Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 32:777-810.
199. Viveros MP, Marco EM, File SE (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331-342.
200. Volkow ND, Baler RD, Compton WM,Weiss SR (2014). Adverse health effects of marijuanause. N Engl J Med 370:2219-2227.
201. Vuchinich RE, Simpson CA (1998). Hyperbolic temporal discounting in social drinkers and problem drinkers. Exp Clin Psychopharmacol 6:292-305.
202. Voon V, Irvine MA, Derbyshire K, Worbe Y, Lange I, Abbott S, et al. (2014). Measuring 'waiting' impulsivity in substance addictions and binge eating disorder in a novel analogue of rodent serial reaction time task. Biol Psychiatry 75:148-155.
203. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003). Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 100:1393-1398.
204. Wills TA, Vaccaro D, McNamara G (1994). Novelty seeking, risk taking, and related constructs as predictors of adolescent substance use: an application of Cloninger's theory. J Subst Abuse 6:1-20.
205. Wilson RI, Nicoll RA (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592.
206. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296:678-682.
207. Winstanley CA (2011). The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol 164: 1301-1321.
208. Wiskerke J, Stoop N, Schetters D, Schoffelmeer AN, Pattij T (2011). Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice. PLoS One 6:e25856.
209. Wiskerke J, van Mourik Y, Schetters D, Schoffelmeer AN, Pattij T (2012). On the role of cannabinoid CB1-and mu-opioid receptors in motor impulsivity. Front Pharmacol 3:108.
210. Wong MM, Nigg JT, Zucker RA, Puttler LI, Fitzgerald HE, Jester JM, et al. (2006). Behavioral control and resiliency in the onset of alcohol and illicit drug use: a prospective study from preschool to adolescence. Child Dev 77:1016-1033.
211. Xi ZX (2011). Medication development for the treatment of cocaine addiction-progress at preclinical and clinical levels in addiction. From pathophysiology to treament. Rijeka, Croatia: InTech; p. 498.
212. Xi ZX, Spiller K, Pak AC, Gilbert J, Dillon C, Li X, et al. (2008). Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with selfadministration and brain-stimulation reward in rats. Neuropsychopharmacology 33:1735-1745.
213. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. (2011). Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-1166.
214. Young RM, Oei TP, Knight RG (1990). The tension reduction hypothesis revisited: an alcohol expectancy perspective. Br J Addict 85:31-40.
215. Zernicke KA, Cantrell H, Finn PR, Lucas J (2010). The association between earlier age of first drink, disinhibited personality, and externalizing psychopathology in young adults. Addict Behav 35:414-418.
216. Zuardi AW (2006). History of cannabis as a medicine: a review. Rev Bras Psiquiatr 28:153-157.